Register
Login:
Share:
Email Facebook Twitter


Exclusive: Hardman & Co call the lithium market: is a change in trend happening?
Tower Resources identify 18 million barrels of contingent reserves worth $118M in Cameroon


Hemogenyx Share Chat (HEMO)



Share Price: 2.15Bid: 2.00Ask: 2.30Change: 0.00 (0.00%)No Movement on Hemogenyx
Spread: 0.30Spread as %: 15.00%Open: 2.15High: 2.15Low: 2.15Yesterday’s Close: 2.15


Share Discussion for Hemogenyx


Thread View

Please login or register to post a message on Share Chat.

Posts per page:

kezzman
Posts: 2,753
Opinion:No Opinion
Price:2.15
RE: oh dear
Thu 14:57
jeez makes me feel slightly better

lets hope 2019 things get better here and the markets

good luck bud
 
Shukan
Posts: 2,092
Opinion:No Opinion
Price:2.15
RE: oh dear
Thu 13:53
October 2019 warrants runout - Only £38K down , Merry Christmas see u in the NYear
kezzman
Posts: 2,753
Opinion:No Opinion
Price:2.15
RE: oh dear
Thu 10:53
worrying times

concerned that we are at the start of bear market so will sit it out with cash for now and watch

might have to average down here at some point and hope if it is a bear market they survive
ontarget
Posts: 1,890
Premium Chat Member
Opinion:No Opinion
Price:2.10
RE: oh dear
Thu 09:36
Bad market combined with a concerted deramping effort going on on advfn. Holders too depressed to stand up to them and no money to take advantage due to every other share in the portfolio in the **** as well.
ontarget
Posts: 1,890
Premium Chat Member
Opinion:No Opinion
Price:2.10
RE: oh dear
Thu 09:34
Neither will Professor Sir Marc Feldmann with his 3.5p/share options he was hoping to be paid with.
A good time for him to average down perhaps?
kezzman
Posts: 2,753
Opinion:No Opinion
Price:2.10
oh dear
Thu 09:09
whats going on here

dragged down with the market

looks like we wont be in the money on our warrants for some time
ontarget
Posts: 1,890
Premium Chat Member
Opinion:No Opinion
Price:2.50
HEMO
5 Dec '18
Could do with an operational update here to update us on the current state of play with the three divisions.
scriven
Posts: 3
Opinion:No Opinion
Price:2.55
orgs news release
30 Nov '18
Last night relating to recent funding with our two subsidiaries orgs up 7.7%
ontarget
Posts: 1,890
Premium Chat Member
Opinion:No Opinion
Price:2.55
RE: Clinical Trials
28 Nov '18
The announcement clearly states "The samples are intended for use as source of autologous insulin producing (AIP) cells", so I don't seen any basis for assuming they will also be used for Hemogenyx related trails.
If they had said something like "and for other products in development" then maybe.
Shukan
Posts: 2,092
Opinion:No Opinion
Price:2.55
RE: Clinical Trials
28 Nov '18
Look beyond that
ontarget
Posts: 1,890
Premium Chat Member
Opinion:No Opinion
Price:2.55
RE: Clinical Trials
28 Nov '18
I'm not sure that (the AIP cells) has anything to do with HEMO though, it's related to Orgenesis' own technologies I believe.
Shukan
Posts: 2,092
Opinion:No Opinion
Price:2.55
RE: Clinical Trials
28 Nov '18
Shukan
Posts: 2,092
Opinion:Strong Buy
Price:2.55
Clinical Trials
28 Nov '18
And look what we have here👇👇👇

GERMANTOWN, Md., Nov. 21, 2018 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS), a developer, service provider and manufacturer of advanced cell therapies, today announced that it has entered into a collaboration agreement with the New York Blood Center (NYBC), one of the largest independent, community-based blood centers in the world. Under the agreement, NYBC will be responsible for establishing the infrastructure to collect, process, test, cryopreserve and biobank sampling materials, including liver biopsies. The samples are intended for use as source of autologous insulin producing (AIP) cells for patients that may be eligible for future clinical trials.
Shukan
Posts: 2,092
Opinion:Strong Buy
Price:2.65
Orgenesis
23 Nov '18
Shukan
Posts: 2,092
Opinion:Strong Buy
Price:2.65
RE: FDA
23 Nov '18
Read between the lines - look at what Orgenesis is doing - Nasdaq Pharma funds this minnow- only one outcome
Shukan
Posts: 2,092
Opinion:Strong Buy
Price:2.65
RE: FDA
23 Nov '18
Shukan
Posts: 2,092
Opinion:Strong Buy
Price:2.65
FDA
23 Nov '18
FDA grants medicine accelerated approval for people with previously untreated acute myeloid #leukemia, the most common type of aggressive leukemia in adults. ow.ly/zUui50jLhXI
scriven
Posts: 3
Opinion:Hold
Price:2.65
Hemo Website
20 Nov '18
Nice to see website now up to date re. new Financial Controller.
Shukan
Posts: 2,092
Opinion:Strong Buy
Price:2.70
RE: Hemo
13 Nov '18
Way above N4P in terms of who is on board and any potential outcome from such collaboration's
FeverClucker
Posts: 663
Opinion:Strong Buy
Price:2.85
RE: Hemo
12 Nov '18
Think this could be next N4P re SP
Tillywhiz
Posts: 27
Premium Chat Member
Opinion:No Opinion
Price:2.70
Hemo
12 Nov '18
A slice of blue in plenty of red
Shukan
Posts: 2,092
Opinion:Strong Buy
Price:2.50
CEO Vered Caplan
7 Nov '18
Quickdraw18
Posts: 8
Opinion:No Opinion
Price:2.50
Mice
6 Nov '18
Any thoughts on revenue we can expect the receive from the mice over next 2>3 yrs?

Based on 1st deal being worth up to $250k for 6 months. I'll value each deal at $500k per annum with 4 agreements in the bag currently.

Seems feasible Hemo could be making $5m>$10m a year or two. Plus if successful i expect contact values to increase.

PS making first buy of thousand £ on Friday. Aiming to time extension of first mouse deal, which believe will validate CDX internal testing. Would also be good to get in before the manufacturing ramp up and hopeful commencement of phase 1 testing.
Shukan
Posts: 2,092
Opinion:Strong Buy
Price:2.50
RE: Collaboration
6 Nov '18
when u see N4P do 30% on a £64K injection - LOL
ontarget
Posts: 1,890
Premium Chat Member
Opinion:No Opinion
Price:2.50
RE: Collaboration
6 Nov '18
People should really watch these videos and then get buying.
Shockingly low amount of interest at the moment.




Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk






Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.